{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T03:59:46Z","timestamp":1772164786817,"version":"3.50.1"},"reference-count":73,"publisher":"American Association for Cancer Research (AACR)","issue":"8","funder":[{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["FKZ:01KI20130"],"award-info":[{"award-number":["FKZ:01KI20130"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["WA 4608\/1-2"],"award-info":[{"award-number":["WA 4608\/1-2"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001736","name":"German Research Foundation","doi-asserted-by":"publisher","award":["WA 4608\/1-2"],"award-info":[{"award-number":["WA 4608\/1-2"]}],"id":[{"id":"10.13039\/501100001736","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Deutsche Forschungsgemeinschaft under Germany's Excellence Strategy","award":["EXC2180-390900677"],"award-info":[{"award-number":["EXC2180-390900677"]}]},{"name":"Wilhelm Sander Stiftung","award":["2016.177.2"],"award-info":[{"award-number":["2016.177.2"]}]},{"DOI":"10.13039\/501100005677","name":"Jos\u00e9 Carreras Leuk\u00e4mie-Stiftung","doi-asserted-by":"publisher","award":["DJCLS 05 R\/2017"],"award-info":[{"award-number":["DJCLS 05 R\/2017"]}],"id":[{"id":"10.13039\/501100005677","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fort\u00fcne Program of the University of T\u00fcbingen","award":["2451-0-0"],"award-info":[{"award-number":["2451-0-0"]}]},{"name":"Fort\u00fcne Program of the University of T\u00fcbingen","award":["2581-0-0"],"award-info":[{"award-number":["2581-0-0"]}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Patients with cancer, in particular patients with hematologic malignancies, are at increased risk for critical illness upon COVID-19. We here assessed antibody as well as CD4+ and CD8+ T-cell responses in unexposed and SARS-CoV-2\u2013infected patients with cancer to characterize SARS-CoV-2 immunity and to identify immunologic parameters contributing to COVID-19 outcome. Unexposed patients with hematologic malignancies presented with reduced prevalence of preexisting SARS-CoV-2 cross-reactive CD4+ T-cell responses and signs of T-cell exhaustion compared with patients with solid tumors and healthy volunteers. Whereas SARS-CoV-2 antibody responses did not differ between patients with COVID-19 and cancer and healthy volunteers, intensity, expandability, and diversity of SARS-CoV-2 T-cell responses were profoundly reduced in patients with cancer, and the latter associated with a severe course of COVID-19. This identifies impaired SARS-CoV-2 T-cell immunity as a potential determinant for dismal outcome of COVID-19 in patients with cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>This first comprehensive analysis of SARS-CoV-2 immune responses in patients with cancer reports on the potential implications of impaired SARS-CoV-2 T-cell responses for understanding pathophysiology and predicting severity of COVID-19, which in turn might allow for the development of therapeutic measures and vaccines for this vulnerable patient population.<\/jats:p>\n                    <jats:p>See related commentary by Salom\u00e9 and Horowitz, p. 1877.<\/jats:p>\n                    <jats:p>This article is highlighted in the In This Issue feature, p. 1861<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2159-8290.cd-21-0191","type":"journal-article","created":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T04:25:13Z","timestamp":1621398313000},"page":"1982-1995","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Preexisting and Post\u2013COVID-19 Immune Responses to SARS-CoV-2 in Patients with Cancer"],"prefix":"10.1158","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8107-0419","authenticated-orcid":false,"given":"Tatjana","family":"Bilich","sequence":"first","affiliation":[{"name":"1Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital T\u00fcbingen, T\u00fcbingen, Germany."},{"name":"2Institute for Cell Biology, Department of Immunology, University of T\u00fcbingen, T\u00fcbingen, Germany."},{"name":"3Cluster of Excellence iFIT (EXC2180) \u201cImage-Guided and Functionally Instructed Tumor Therapies,\u201d University of T\u00fcbingen, T\u00fcbingen, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7283-9778","authenticated-orcid":false,"given":"Malte","family":"Roerden","sequence":"additional","affiliation":[{"name":"2Institute for Cell Biology, Department of Immunology, University of T\u00fcbingen, T\u00fcbingen, Germany."},{"name":"3Cluster of Excellence iFIT (EXC2180) \u201cImage-Guided and Functionally Instructed Tumor Therapies,\u201d University of T\u00fcbingen, T\u00fcbingen, Germany."},{"name":"4Department of Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital T\u00fcbingen, T\u00fcbingen, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2197-8740","authenticated-orcid":false,"given":"Yacine","family":"Maringer","sequence":"additional","affiliation":[{"name":"1Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital T\u00fcbingen, T\u00fcbingen, Germany."},{"name":"2Institute for Cell Biology, Department of Immunology, University of T\u00fcbingen, T\u00fcbingen, Germany."},{"name":"3Cluster of Excellence iFIT (EXC2180) \u201cImage-Guided and Functionally Instructed Tumor Therapies,\u201d University of T\u00fcbingen, T\u00fcbingen, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8504-8481","authenticated-orcid":false,"given":"Annika","family":"Nelde","sequence":"additional","affiliation":[{"name":"1Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital T\u00fcbingen, T\u00fcbingen, Germany."},{"name":"2Institute for Cell Biology, Department of Immunology, University of T\u00fcbingen, T\u00fcbingen, Germany."},{"name":"3Cluster of Excellence iFIT (EXC2180) \u201cImage-Guided and Functionally Instructed Tumor Therapies,\u201d University of T\u00fcbingen, T\u00fcbingen, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonas S.","family":"Heitmann","sequence":"additional","affiliation":[{"name":"1Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital T\u00fcbingen, T\u00fcbingen, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4930-1467","authenticated-orcid":false,"given":"Marissa L.","family":"Dubbelaar","sequence":"additional","affiliation":[{"name":"1Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital T\u00fcbingen, T\u00fcbingen, Germany."},{"name":"2Institute for Cell Biology, Department of Immunology, University of T\u00fcbingen, T\u00fcbingen, Germany."},{"name":"3Cluster of Excellence iFIT (EXC2180) \u201cImage-Guided and Functionally Instructed Tumor Therapies,\u201d University of T\u00fcbingen, T\u00fcbingen, Germany."},{"name":"5Quantitative Biology Center (QBiC), University of T\u00fcbingen, T\u00fcbingen, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Peter","sequence":"additional","affiliation":[{"name":"6Institute for Clinical Chemistry and Pathobiochemistry, Department for Diagnostic Laboratory Medicine, University Hospital T\u00fcbingen, T\u00fcbingen, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5718-1530","authenticated-orcid":false,"given":"Sebastian","family":"H\u00f6rber","sequence":"additional","affiliation":[{"name":"6Institute for Clinical Chemistry and Pathobiochemistry, Department for Diagnostic Laboratory Medicine, University Hospital T\u00fcbingen, T\u00fcbingen, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens","family":"Bauer","sequence":"additional","affiliation":[{"name":"1Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital T\u00fcbingen, T\u00fcbingen, Germany."},{"name":"2Institute for Cell Biology, Department of Immunology, University of T\u00fcbingen, T\u00fcbingen, Germany."},{"name":"3Cluster of Excellence iFIT (EXC2180) \u201cImage-Guided and Functionally Instructed Tumor Therapies,\u201d University of T\u00fcbingen, T\u00fcbingen, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonas","family":"Rieth","sequence":"additional","affiliation":[{"name":"1Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital T\u00fcbingen, T\u00fcbingen, Germany."},{"name":"2Institute for Cell Biology, Department of Immunology, University of T\u00fcbingen, T\u00fcbingen, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8185-140X","authenticated-orcid":false,"given":"Marcel","family":"Wacker","sequence":"additional","affiliation":[{"name":"1Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital T\u00fcbingen, T\u00fcbingen, Germany."},{"name":"2Institute for Cell Biology, Department of Immunology, University of T\u00fcbingen, T\u00fcbingen, Germany."},{"name":"3Cluster of Excellence iFIT (EXC2180) \u201cImage-Guided and Functionally Instructed Tumor Therapies,\u201d University of T\u00fcbingen, T\u00fcbingen, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fiamma","family":"Berner","sequence":"additional","affiliation":[{"name":"7Institute of Immunobiology, Kantonsspital St. Gallen, St. Gallen, Switzerland."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lukas","family":"Flatz","sequence":"additional","affiliation":[{"name":"7Institute of Immunobiology, Kantonsspital St. Gallen, St. Gallen, Switzerland."},{"name":"8Department of Dermatology, University Hospital T\u00fcbingen, T\u00fcbingen, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefanie","family":"Held","sequence":"additional","affiliation":[{"name":"9Department for Hematology and Oncology, University Hospital Bonn, Bonn, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Brossart","sequence":"additional","affiliation":[{"name":"9Department for Hematology and Oncology, University Hospital Bonn, Bonn, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2920-3894","authenticated-orcid":false,"given":"Melanie","family":"M\u00e4rklin","sequence":"additional","affiliation":[{"name":"1Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital T\u00fcbingen, T\u00fcbingen, Germany."},{"name":"3Cluster of Excellence iFIT (EXC2180) \u201cImage-Guided and Functionally Instructed Tumor Therapies,\u201d University of T\u00fcbingen, T\u00fcbingen, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp","family":"Wagner","sequence":"additional","affiliation":[{"name":"10Department of Obstetrics and Gynecology, University Hospital of T\u00fcbingen, T\u00fcbingen, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Erne","sequence":"additional","affiliation":[{"name":"11Department of Urology, Medical Faculty and University Hospital, Eberhard-Karls-University T\u00fcbingen, T\u00fcbingen, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6111-3901","authenticated-orcid":false,"given":"Reinhild","family":"Klein","sequence":"additional","affiliation":[{"name":"4Department of Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital T\u00fcbingen, T\u00fcbingen, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans-Georg","family":"Rammensee","sequence":"additional","affiliation":[{"name":"2Institute for Cell Biology, Department of Immunology, University of T\u00fcbingen, T\u00fcbingen, Germany."},{"name":"3Cluster of Excellence iFIT (EXC2180) \u201cImage-Guided and Functionally Instructed Tumor Therapies,\u201d University of T\u00fcbingen, T\u00fcbingen, Germany."},{"name":"12German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), partner site T\u00fcbingen, T\u00fcbingen, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6719-1847","authenticated-orcid":false,"given":"Helmut R.","family":"Salih","sequence":"additional","affiliation":[{"name":"1Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital T\u00fcbingen, T\u00fcbingen, Germany."},{"name":"3Cluster of Excellence iFIT (EXC2180) \u201cImage-Guided and Functionally Instructed Tumor Therapies,\u201d University of T\u00fcbingen, T\u00fcbingen, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliane S.","family":"Walz","sequence":"additional","affiliation":[{"name":"1Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital T\u00fcbingen, T\u00fcbingen, Germany."},{"name":"2Institute for Cell Biology, Department of Immunology, University of T\u00fcbingen, T\u00fcbingen, Germany."},{"name":"3Cluster of Excellence iFIT (EXC2180) \u201cImage-Guided and Functionally Instructed Tumor Therapies,\u201d University of T\u00fcbingen, T\u00fcbingen, Germany."},{"name":"13Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology and Robert Bosch Center for Tumor Diseases (RBCT), Stuttgart, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1086","published-online":{"date-parts":[[2021,5,19]]},"reference":[{"key":"2022060711563174900_bib1","first-page":"e00187","article-title":"Emergence of a novel coronavirus, severe acute respiratory syndrome coronavirus 2: biology and therapeutic options","volume":"58","author":"Khan","year":"2020","journal-title":"J Clin Microbiol"},{"key":"2022060711563174900_bib2","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet"},{"key":"2022060711563174900_bib3","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1001\/jama.2020.3204","article-title":"Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore","volume":"323","author":"Young","year":"2020","journal-title":"JAMA"},{"key":"2022060711563174900_bib4","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1001\/jama.2020.7202","article-title":"Characteristics of hospitalized adults with COVID-19 in an integrated health care system in California","volume":"323","author":"Myers","year":"2020","journal-title":"JAMA"},{"key":"2022060711563174900_bib5","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1001\/jama.2020.6775","article-title":"Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York city area","volume":"323","author":"Richardson","year":"2020","journal-title":"JAMA"},{"key":"2022060711563174900_bib6","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/S1470-2045(20)30310-7","article-title":"Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study","volume":"21","author":"Yang","year":"2020","journal-title":"Lancet Oncol"},{"key":"2022060711563174900_bib7","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1158\/2159-8290.CD-20-0941","article-title":"Utilization of COVID-19 treatments and clinical outcomes among patients with cancer: a COVID-19 and Cancer Consortium (CCC19) cohort study","volume":"10","author":"Rivera","year":"2020","journal-title":"Cancer Discov"},{"key":"2022060711563174900_bib8","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1038\/s41591-020-0979-0","article-title":"Determinants of COVID-19 disease severity in patients with cancer","volume":"26","author":"Robilotti","year":"2020","journal-title":"Nat Med"},{"key":"2022060711563174900_bib9","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1158\/2159-8290.CD-20-0422","article-title":"Patients with cancer appear more vulnerable to SARS-COV-2: a multicenter study during the COVID-19 outbreak","volume":"10","author":"Dai","year":"2020","journal-title":"Cancer Discov"},{"key":"2022060711563174900_bib10","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1016\/S0140-6736(20)31173-9","article-title":"COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study","volume":"395","author":"Lee","year":"2020","journal-title":"Lancet"},{"key":"2022060711563174900_bib11","doi-asserted-by":"crossref","first-page":"4627","DOI":"10.1002\/cncr.27447","article-title":"A multicenter study of pandemic influenza A (H1N1) infection in patients with solid tumors in 3 countries: early therapy improves outcomes","volume":"118","author":"Chemaly","year":"2012","journal-title":"Cancer"},{"key":"2022060711563174900_bib12","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ccell.2020.07.006","article-title":"Cancer patients and risk of mortality for COVID-19","volume":"38","author":"Curigliano","year":"2020","journal-title":"Cancer Cell"},{"key":"2022060711563174900_bib13","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1080\/23744235.2019.1592217","article-title":"High mortality from viral pneumonia in patients with cancer","volume":"51","author":"Kim","year":"2019","journal-title":"Infect Dis"},{"key":"2022060711563174900_bib14","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13027-015-0039-4","article-title":"Cytomegalovirus reactivation and its clinical impact in patients with solid tumors","volume":"10","author":"Schlick","year":"2015","journal-title":"Infect Agent Cancer"},{"key":"2022060711563174900_bib15","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/S0140-6736(09)60221-X","article-title":"Multiple myeloma","volume":"374","author":"Raab","year":"2009","journal-title":"Lancet"},{"key":"2022060711563174900_bib16","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.ccell.2018.03.012","article-title":"T cell dysfunction in cancer","volume":"33","author":"Thommen","year":"2018","journal-title":"Cancer Cell"},{"key":"2022060711563174900_bib17","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1038\/s41375-020-0966-y","article-title":"Reply to \u201cCLL and COVID-19 at the Hospital Clinic of Barcelona: an interim report\u201d Analysis of six hematological centers in Lombardy","volume":"34","author":"Reda","year":"2020","journal-title":"Leukemia"},{"key":"2022060711563174900_bib18","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1182\/blood.2020006288","article-title":"The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19\u2013infected patients","volume":"135","author":"Treon","year":"2020","journal-title":"Blood"},{"key":"2022060711563174900_bib19","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1038\/s41375-020-01030-2","article-title":"Anti-SARS-CoV-2 antibody response in patients with chronic lymphocytic leukemia","volume":"34","author":"Roeker","year":"2020","journal-title":"Leukemia"},{"key":"2022060711563174900_bib20","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41375-020-01103-2","article-title":"SARS-CoV-2 antibody responses in patients with acute leukaemia","volume":"35","author":"O'Nions","year":"2021","journal-title":"Leukemia"},{"key":"2022060711563174900_bib21","doi-asserted-by":"crossref","first-page":"eabd2071","DOI":"10.1126\/sciimmunol.abd2071","article-title":"Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome","volume":"5","author":"Weiskopf","year":"2020","journal-title":"Sci Immunol"},{"key":"2022060711563174900_bib22","doi-asserted-by":"crossref","first-page":"eabf4063","DOI":"10.1126\/science.abf4063","article-title":"Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection","volume":"371","author":"Dan","year":"2021","journal-title":"Science"},{"key":"2022060711563174900_bib23","doi-asserted-by":"crossref","first-page":"eabf7517","DOI":"10.1126\/scitranslmed.abf7517","article-title":"T cell and antibody kinetics delineate SARS-CoV-2 peptides mediating long-term immune responses in COVID-19 convalescent individuals","volume":"13","author":"Bilich","year":"2021","journal-title":"Sci Transl Med"},{"key":"2022060711563174900_bib24","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41590-020-00808-x","article-title":"SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition","volume":"22","author":"Nelde","year":"2021","journal-title":"Nat Immunol"},{"key":"2022060711563174900_bib25","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/s41586-020-2550-z","article-title":"SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls","volume":"584","author":"Le Bert","year":"2020","journal-title":"Nature"},{"key":"2022060711563174900_bib26","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.cell.2020.05.015","article-title":"Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals","volume":"181","author":"Grifoni","year":"2020","journal-title":"Cell"},{"key":"2022060711563174900_bib27","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2598-9","article-title":"SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19","volume":"587","author":"Braun","year":"2020","journal-title":"Nature"},{"key":"2022060711563174900_bib28","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1126\/science.abd3871","article-title":"Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans","volume":"370","author":"Mateus","year":"2020","journal-title":"Science"},{"key":"2022060711563174900_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2172-9-1","article-title":"HLA class I supertypes: a revised and updated classification","volume":"9","author":"Sidney","year":"2008","journal-title":"BMC Immunol"},{"key":"2022060711563174900_bib30","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1038\/s41591-020-1038-6","article-title":"A dynamic COVID-19 immune signature includes associations with poor prognosis","volume":"26","author":"Laing","year":"2020","journal-title":"Nat Med"},{"key":"2022060711563174900_bib31","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/s41392-020-00301-9","article-title":"Disease severity dictates SARS-CoV-2-specific neutralizing antibody responses in COVID-19","volume":"5","author":"Chen","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"2022060711563174900_bib32","doi-asserted-by":"crossref","first-page":"100204","DOI":"10.1016\/j.xcrm.2021.100204","article-title":"Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases","volume":"2","author":"Tarke","year":"2021","journal-title":"Cell Rep Med"},{"key":"2022060711563174900_bib33","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1084\/jem.20071140","article-title":"Age-associated decline in T cell repertoire diversity leads to holes in the repertoire and impaired immunity to influenza virus","volume":"205","author":"Yager","year":"2008","journal-title":"J Exp Med"},{"key":"2022060711563174900_bib34","doi-asserted-by":"crossref","first-page":"e737","DOI":"10.1016\/S2352-3026(20)30251-9","article-title":"Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study","volume":"7","author":"Passamonti","year":"2020","journal-title":"Lancet Haematol"},{"key":"2022060711563174900_bib35","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1001\/jamaoncol.2020.0980","article-title":"SARS-CoV-2 transmission in patients with cancer at a tertiary care hospital in Wuhan, China","volume":"6","author":"Yu","year":"2020","journal-title":"JAMA Oncol"},{"key":"2022060711563174900_bib36","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/S0140-6736(20)31187-9","article-title":"Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study","volume":"395","author":"Kuderer","year":"2020","journal-title":"Lancet"},{"key":"2022060711563174900_bib37","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/icb.2010.61","article-title":"Memory CD8+ T cells from naturally acquired primary dengue virus infection are highly cross-reactive","volume":"89","author":"Friberg","year":"2011","journal-title":"Immunol Cell Biol"},{"key":"2022060711563174900_bib38","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.immuni.2012.10.021","article-title":"Virus-specific CD4(+) memory-phenotype T cells are abundant in unexposed adults","volume":"38","author":"Su","year":"2013","journal-title":"Immunity"},{"key":"2022060711563174900_bib39","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1615\/CritRevImmunol.v32.i4.50","article-title":"Cross-reactivity of T cells and its role in the immune system","volume":"32","author":"Petrova","year":"2012","journal-title":"Crit Rev Immunol"},{"key":"2022060711563174900_bib40","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1128\/JVI.01743-10","article-title":"Characterization of cross-reactive CD8+ T-cell recognition of HLA-A2-restricted HIV-Gag (SLYNTVATL) and HCV-NS5b (ALYDVVSKL) epitopes in individuals infected with human immunodeficiency and hepatitis C viruses","volume":"85","author":"Vali","year":"2011","journal-title":"J Virol"},{"key":"2022060711563174900_bib41","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.0105-2896.2010.00897.x","article-title":"Heterologous immunity between viruses","volume":"235","author":"Welsh","year":"2010","journal-title":"Immunol Rev"},{"key":"2022060711563174900_bib42","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/j.jaci.2017.05.037","article-title":"Unique influenza A cross-reactive memory CD8 T-cell receptor repertoire has a potential to protect against EBV seroconversion","volume":"140","author":"Watkin","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"2022060711563174900_bib43","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/s41577-020-00460-4","article-title":"Cross-reactive memory T cells and herd immunity to SARS-CoV-2","volume":"20","author":"Lipsitch","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"2022060711563174900_bib44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-020-78506-9","article-title":"Older adults lack SARS CoV-2 cross-reactive T lymphocytes directed to human coronaviruses OC43 and NL63","volume":"10","author":"Saletti","year":"2020","journal-title":"Sci Rep"},{"key":"2022060711563174900_bib45","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/nm.2612","article-title":"Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans","volume":"18","author":"Wilkinson","year":"2012","journal-title":"Nat Med"},{"key":"2022060711563174900_bib46","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.4049\/jimmunol.177.4.2138","article-title":"Screening and identification of severe acute respiratory syndrome-associated coronavirus-specific CTL epitopes","volume":"177","author":"Zhou","year":"2006","journal-title":"J Immunol"},{"key":"2022060711563174900_bib47","doi-asserted-by":"crossref","first-page":"123ra25","DOI":"10.1126\/scitranslmed.3003165","article-title":"HIV-specific cytolytic CD4 T cell responses during acute HIV infection predict disease outcome","volume":"4","author":"Soghoian","year":"2012","journal-title":"Sci Transl Med"},{"key":"2022060711563174900_bib48","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.cell.2021.01.007","article-title":"Adaptive immunity to SARS-CoV-2 and COVID-19","volume":"184","author":"Sette","year":"2021","journal-title":"Cell"},{"key":"2022060711563174900_bib49","doi-asserted-by":"crossref","first-page":"4547","DOI":"10.1158\/1078-0432.CCR-07-0708","article-title":"Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells","volume":"13","author":"May","year":"2007","journal-title":"Clin Cancer Res"},{"key":"2022060711563174900_bib50","doi-asserted-by":"crossref","first-page":"4295","DOI":"10.1158\/1078-0432.CCR-13-1432","article-title":"License to kill\u201d reflects joint action of CD4 and CD8 T cells","volume":"19","author":"Melief","year":"2013","journal-title":"Clin Cancer Res"},{"key":"2022060711563174900_bib51","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1365-2249.2008.03856.x","article-title":"High-affinity human leucocyte antigen class I binding variola-derived peptides induce CD4+ T cell responses more than 30 years post-vaccinia virus vaccination","volume":"155","author":"Wang","year":"2009","journal-title":"Clin Exp Immunol"},{"key":"2022060711563174900_bib52","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1365-2567.2004.01857.x","article-title":"Major histocompatibility complex class I-restricted alloreactive CD4+ T cells","volume":"112","author":"Boyle","year":"2004","journal-title":"Immunology"},{"key":"2022060711563174900_bib53","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1172\/JCI119559","article-title":"Human histocompatibility leukocyte antigen-binding supermotifs predict broadly cross-reactive cytotoxic T lymphocyte responses in patients with acute hepatitis","volume":"100","author":"Bertoni","year":"1997","journal-title":"J Clin Invest"},{"key":"2022060711563174900_bib54","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.4049\/jimmunol.171.3.1407","article-title":"Promiscuous CTL recognition of viral epitopes on multiple human leukocyte antigens: biological validation of the proposed HLA A24 supertype","volume":"171","author":"Burrows","year":"2003","journal-title":"J Immunol"},{"key":"2022060711563174900_bib55","doi-asserted-by":"crossref","first-page":"13980","DOI":"10.1073\/pnas.0506768102","article-title":"HLA class I-restricted responses to vaccinia recognize a broad array of proteins mainly involved in virulence and viral gene regulation","volume":"102","author":"Oseroff","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022060711563174900_bib56","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1016\/j.vaccine.2007.01.020","article-title":"HLA supertypes and immune responses to measles\u2013mumps\u2013rubella viral vaccine: findings and implications for vaccine design","volume":"25","author":"Ovsyannikova","year":"2007","journal-title":"Vaccine"},{"key":"2022060711563174900_bib57","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.0001-2815.2004.00221.x","article-title":"SARS CTL vaccine candidates; HLA supertype-, genome-wide scanning and biochemical validation","volume":"63","author":"Sylvester-Hvid","year":"2004","journal-title":"Tissue Antigens"},{"key":"2022060711563174900_bib58","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/nm893","article-title":"Advantage of rare HLA supertype in HIV disease progression","volume":"9","author":"Trachtenberg","year":"2003","journal-title":"Nat Med"},{"key":"2022060711563174900_bib59","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1086\/315472","article-title":"Influence of HLA supertypes on susceptibility and resistance to human immunodeficiency virus type 1 infection","volume":"181","author":"MacDonald","year":"2000","journal-title":"J Infect Dis"},{"key":"2022060711563174900_bib60","first-page":"805","article-title":"Human leukocyte antigen class I supertypes influence susceptibility and severity of tuberculosis","volume":"189","author":"Balamurugan","year":"2004","journal-title":"Nat Rev Immunol"},{"key":"2022060711563174900_bib61","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1038\/leu.2008.374","article-title":"Strong association of the HLA-DP6 supertype with childhood leukaemia is due to a single allele, DPB1* 0601","volume":"23","author":"Taylor","year":"2009","journal-title":"Leukemia"},{"key":"2022060711563174900_bib62","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"2022060711563174900_bib63","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1172\/JCI59806","article-title":"IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma","volume":"122","author":"Yang","year":"2012","journal-title":"J Clin Invest"},{"key":"2022060711563174900_bib64","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1182\/blood-2012-09-457531","article-title":"T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production","volume":"121","author":"Riches","year":"2013","journal-title":"Blood"},{"key":"2022060711563174900_bib65","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1182\/asheducation-2006.1.368","article-title":"Viral infections in patients with hematological malignancies","volume":"2006","author":"Wade","year":"2006","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2022060711563174900_bib66","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.idc.2019.01.001","article-title":"Chemotherapy and beyond: infections in the era of old and new treatments for hematologic malignancies","volume":"33","author":"Atkins","year":"2019","journal-title":"Infect Dis Clin North Am"},{"key":"2022060711563174900_bib67","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/s41586-020-2380-z","article-title":"Human neutralizing antibodies elicited by SARS-CoV-2 infection","volume":"584","author":"Ju","year":"2020","journal-title":"Nature"},{"key":"2022060711563174900_bib68","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa043951","article-title":"Respiratory syncytial virus infection in elderly and high-risk adults","volume":"352","author":"Falsey","year":"2005","journal-title":"N Engl J Med"},{"key":"2022060711563174900_bib69","doi-asserted-by":"crossref","first-page":"e0148258","DOI":"10.1371\/journal.pone.0148258","article-title":"Long-term shedding of influenza virus, parainfluenza virus, respiratory syncytial virus and nosocomial epidemiology in patients with hematological disorders","volume":"11","author":"Lehners","year":"2016","journal-title":"PLoS One"},{"key":"2022060711563174900_bib70","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-020-17292-4","article-title":"Marked T cell activation, senescence, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia","volume":"11","author":"De Biasi","year":"2020","journal-title":"Nat Commun"},{"key":"2022060711563174900_bib71","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nri.2017.112","article-title":"Immune checkpoint blockade in infectious diseases","volume":"18","author":"Wykes","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"2022060711563174900_bib72","doi-asserted-by":"crossref","first-page":"e001145","DOI":"10.1136\/jitc-2020-001145","article-title":"On the use of immune checkpoint inhibitors in patients with viral infections including COVID-19","volume":"8","author":"Gambichler","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2022060711563174900_bib73","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/1471-2105-7-153","article-title":"Predicting population coverage of T-cell epitope-based diagnostics and vaccines","volume":"7","author":"Bui","year":"2006","journal-title":"BMC Bioinformatics"}],"container-title":["Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/11\/8\/1982\/3102557\/1982.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/11\/8\/1982\/3102557\/1982.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T08:33:07Z","timestamp":1654590787000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/11\/8\/1982\/666202\/Preexisting-and-Post-COVID-19-Immune-Responses-to"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,19]]},"references-count":73,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,5,19]]},"published-print":{"date-parts":[[2021,8,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2159-8290.cd-21-0191","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/2159-8290.22539212.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22539212","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.c.6549020.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.c.6549020","asserted-by":"object"}]},"ISSN":["2159-8274","2159-8290"],"issn-type":[{"value":"2159-8274","type":"print"},{"value":"2159-8290","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,19]]}}}